Zetterberg H - Search Results

1

Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases.

Lleó A, Cavedo E, Parnetti L, Vanderstichele H, Herukka SK, Andreasen N, Ghidoni R, Lewczuk P, Jeromin A, Winblad B, Tsolaki M, Mroczko B, Visser PJ, Santana I, Svenningsson P, Blennow K, Aarsland D, Molinuevo JL, Zetterberg H, Mollenhauer B. Lleó A, et al. Among authors: zetterberg h. Nat Rev Neurol. 2015 Jan;11(1):41-55. doi: 10.1038/nrneurol.2014.232. Epub 2014 Dec 16. Nat Rev Neurol. 2015. PMID: 25511894 Review.

2

The transcobalamin (TC) codon 259 genetic polymorphism influences holo-TC concentration in cerebrospinal fluid from patients with Alzheimer disease.

Zetterberg H, Nexö E, Regland B, Minthon L, Boson R, Palmér M, Rymo L, Blennow K. Zetterberg H, et al. Clin Chem. 2003 Jul;49(7):1195-8. doi: 10.1373/49.7.1195. Clin Chem. 2003. PMID: 12816923 No abstract available.

3

Cerebrospinal fluid markers for prediction of Alzheimer's disease.

Zetterberg H, Wahlund LO, Blennow K. Zetterberg H, et al. Neurosci Lett. 2003 Nov 27;352(1):67-9. doi: 10.1016/j.neulet.2003.08.011. Neurosci Lett. 2003. PMID: 14615052

4

Variants of CYP46A1 may interact with age and APOE to influence CSF Abeta42 levels in Alzheimer's disease.

Johansson A, Katzov H, Zetterberg H, Feuk L, Johansson B, Bogdanovic N, Andreasen N, Lenhard B, Brookes AJ, Pedersen NL, Blennow K, Prince JA. Johansson A, et al. Among authors: zetterberg h. Hum Genet. 2004 May;114(6):581-7. doi: 10.1007/s00439-004-1107-9. Epub 2004 Mar 18. Hum Genet. 2004. PMID: 15034781

5

APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42.

Prince JA, Zetterberg H, Andreasen N, Marcusson J, Blennow K. Prince JA, et al. Among authors: zetterberg h. Neurology. 2004 Jun 8;62(11):2116-8. doi: 10.1212/01.wnl.0000128088.08695.05. Neurology. 2004. PMID: 15184629

6

Increased cerebrospinal fluid levels of transforming growth factor-beta1 in Alzheimer's disease.

Zetterberg H, Andreasen N, Blennow K. Zetterberg H, et al. Neurosci Lett. 2004 Sep 2;367(2):194-6. doi: 10.1016/j.neulet.2004.06.001. Neurosci Lett. 2004. PMID: 15331151

7

Elevated total tau/phospho-tau ratio in autopsy-proven Creutzfeldt-Jakob disease with negative 14-3-3 test results.

Zetterberg H, Blennow K. Zetterberg H, et al. Neurol Sci. 2004 Dec;25(5):301-2. doi: 10.1007/s10072-004-0358-5. Neurol Sci. 2004. PMID: 15624089 No abstract available.

8

Evaluation of factors of importance for clinical dementia diagnosis.

Nagga K, Garcia J, Zetterberg H, Blennow K, Gottfries J, Marcusson J. Nagga K, et al. Among authors: zetterberg h. Dement Geriatr Cogn Disord. 2005;19(5-6):289-98. doi: 10.1159/000084554. Epub 2005 Mar 18. Dement Geriatr Cogn Disord. 2005. PMID: 15775718 Free article.

9

[New investigations in suspected Creutzfeldt-Jakob disease. Analysis of 14-3-3 protein and T-tau in cerebrospinal fluid for safer diagnosis].

Zetterberg H, Hammarin AL, Nilsson P, Andersson E, Lind B, Blennow K. Zetterberg H, et al. Lakartidningen. 2005 Mar 21-Apr 3;102(12-13):956-8, 960-1. Lakartidningen. 2005. PMID: 15887642 Swedish.

10

Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF.

Rüetschi U, Zetterberg H, Podust VN, Gottfries J, Li S, Hviid Simonsen A, McGuire J, Karlsson M, Rymo L, Davies H, Minthon L, Blennow K. Rüetschi U, et al. Among authors: zetterberg h. Exp Neurol. 2005 Dec;196(2):273-81. doi: 10.1016/j.expneurol.2005.08.002. Epub 2005 Sep 8. Exp Neurol. 2005. PMID: 16154129

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,240 results

Search Page